-- 上海復星医薬（上海証券取引所：600196、香港証券取引所：2196）傘下の耀薬業が製造販売するニトロプルシドナトリウム注射剤の医薬品登録申請が、中国国家薬品監督管理局により承認されたことが、木曜日に香港証券取引所に提出された書類で明らかになった。 承認された適応症は、高血圧緊急症および急性心不全である。
Related Articles
Australia
Argus Cuts Price Target on Thermo Fisher Scientific to $560 From $610
Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $478.09, Change: $+11.83, Percent Change: +2.54%
$TMO
Australia
JPMorgan Adjusts Price Target on Royal Caribbean Group to $345 From $341, Maintains Overweight Rating
Royal Caribbean Group (RCL) has an average rating of overweight and mean price target of $345.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $266.70, Change: $+12.69, Percent Change: +5.00%
$RCL
Australia
HSBC Cuts Microsoft Price Target to $571 From $593
Microsoft (MSFT) has an average rating of Buy and mean price target of $562.51, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $403.97, Change: $-20.50, Percent Change: -4.83%
$MSFT